Last reviewed · How we verify

Calcitriol (Rocaltrol®)

Joslin Diabetes Center · FDA-approved active Small molecule

Calcitriol is the active form of vitamin D that binds to vitamin D receptors to regulate calcium and phosphate homeostasis and promote bone mineralization.

Calcitriol is the active form of vitamin D that binds to vitamin D receptors to regulate calcium and phosphate homeostasis and promote bone mineralization. Used for Hypocalcemia in patients with chronic kidney disease, Hypoparathyroidism, Vitamin D-dependent rickets.

At a glance

Generic nameCalcitriol (Rocaltrol®)
Also known asCalcijex®, Rocaltrol®
SponsorJoslin Diabetes Center
Drug classVitamin D analog
TargetVitamin D receptor (VDR)
ModalitySmall molecule
Therapeutic areaEndocrinology
PhaseFDA-approved

Mechanism of action

Calcitriol (1,25-dihydroxyvitamin D3) is the hormonally active metabolite of vitamin D that acts as a ligand for the vitamin D receptor (VDR), a nuclear receptor that regulates gene transcription. It increases intestinal absorption of calcium and phosphate, promotes bone mineralization, and modulates parathyroid hormone secretion to maintain serum calcium and phosphate levels within normal ranges.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: